Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q1 2027 · 10-Q
Revenue$0.00$0.00— vs Q1 2026 Net Income-$75.84K-$75.84KN/M vs Q1 2026 EPS Diluted$0.00$0.00— vs Q1 2026 Operating Income-$75,844N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
ended Apr 30, 2026 · filed Jun 17, 2026 · 48 d after period end